Isabelle is President and CEO of Seventure Partners and manages the Life Sciences team.
Seventure Partners i a Paris-based venture capital organization focused on innovation in life sciences and ICT. The broad focus areas within life sciences are therapeutics, medical devices and diagnostics and nutrition. The specific "core" of Seventure's investment strategy is "health, biotech, nutrition and wellness", with particular focus on the microbiome.
Isabelle brings 25 years of international experience in life sciences business development and finance.
Formerly, Isabelle started her career in '91 at Arthur Andersen Detroit, US then at Pfizer France and Pfizer Europe where she held several positions during 6 years in the field of management accounting, clinical research then Business Development. Since '98, she was Associate Director of Business Development at Fournier/Abbott and signed several deals in Europe and in the US.
Isabelle graduated as an engineer from Ecole Centrale of Paris and holds DECF and ISEB degrees and joined Seventure in July 2001 to create the life sciences department.
Isabelle leads the life sciences team and makes direct investments, mainly in France and Scandinavia and in the US/Canada with a focus on biotech, nutrition, personalized medicine and especially microbiome.
Isabelle’s trackrecord includes Santaris (sold to Roche for $450 millions in august 2014), Argenx (listed), OPI pharma (sold to Eusa for Euro 110 millions), Bioalliance (listed), Pixium Vision (listed), as well as Enterome Bioscience, Maat Pharma and Targedys.